All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Less than a week after Cell Therapeutics Inc. (CTI) snagged a handsome deal with Baxter International Inc. for its Janus kinase (JAK) inhibitor pacritinib – adding another industry vote for the approach – Sanofi SA disclosed safety problems with its JAK inhibitor fedratinib and ended the Phase III effort, which sparked a new look at the class.